These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 25242535)
1. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo. Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535 [TBL] [Abstract][Full Text] [Related]
2. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo. Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394 [TBL] [Abstract][Full Text] [Related]
3. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells. Yuan S; Lei S; Wu S Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592 [TBL] [Abstract][Full Text] [Related]
4. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo. Wang GM; Ren ZX; Wang PS; Su C; Zhang WX; Liu ZG; Zhang L; Zhao XJ; Chen G Oncol Rep; 2014 Aug; 32(2):573-80. PubMed ID: 24899100 [TBL] [Abstract][Full Text] [Related]
5. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells. Liu S; Zhang W; Liu K; Ji B; Wang G Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956 [TBL] [Abstract][Full Text] [Related]
6. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma. Liu Y; Zhang W; Liu S; Liu K; Ji B; Wang Y Oncol Rep; 2017 Mar; 37(3):1857-1864. PubMed ID: 28184920 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells. Yue Y; Shao Y; Luo Q; Shi L; Wang Z Biomed Res Int; 2013; 2013():434561. PubMed ID: 23936798 [TBL] [Abstract][Full Text] [Related]
8. Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis. Chen CL; Wu JC; Chen GY; Yuan PH; Tseng YW; Li KC; Hwang SM; Hu YC Mol Ther; 2015 Jan; 23(1):79-88. PubMed ID: 25023326 [TBL] [Abstract][Full Text] [Related]
9. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536 [TBL] [Abstract][Full Text] [Related]
10. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051 [TBL] [Abstract][Full Text] [Related]
11. Knockdown of ADAM10 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis. Li D; Xiao Z; Wang G; Song X Mol Med Rep; 2015 Oct; 12(4):5517-23. PubMed ID: 26135838 [TBL] [Abstract][Full Text] [Related]
13. Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of microRNA-122-5p to regulate ADAM10 expression. Gao J; Yin X; Yu X; Dai C; Zhou F J Cell Biochem; 2019 Oct; 120(10):16393-16407. PubMed ID: 31270840 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma. Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866 [TBL] [Abstract][Full Text] [Related]
15. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10. Xu Y; Lai Y; Cao L; Li Y; Chen G; Chen L; Weng H; Chen T; Wang L; Ye Y RNA Biol; 2021 Oct; 18(10):1408-1423. PubMed ID: 33206588 [TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3. Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582 [TBL] [Abstract][Full Text] [Related]
17. Taurolidine promotes cell apoptosis by enhancing GRIM‑19 expression in liver cancer. Li F; Qi J; Qin C; Fu Z; Ren W Oncol Rep; 2018 Dec; 40(6):3743-3751. PubMed ID: 30272302 [TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA survivin and GRIM-19 co-expression salmonella plasmid inhibited the growth of laryngeal cancer cells in vitro and in vivo. Wen LJ; Gao LF; Jin CS; Zhang HJ; Ji K; Yang JP; Zhao XJ; Wen MJ; Guan GF Int J Clin Exp Pathol; 2013; 6(10):2071-81. PubMed ID: 24133585 [TBL] [Abstract][Full Text] [Related]
19. Additive effects of eukaryotic co‑expression plasmid carrying GRIM‑19 and LKB1 genes on breast cancer in vitro and in vivo. Zhang W; Shao Y; Du Y; Geng W; Jiang T; Liu H; Zhang D Mol Med Rep; 2015 Nov; 12(5):7665-72. PubMed ID: 26458553 [TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19. Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]